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Abstract
The development of evidence to demonstrate ‘value for money’ is regarded as an important step in facilitating the search for 
the optimal allocation of limited resources and has become an essential component in healthcare decision making. Real-world 
evidence collected from de-identified individuals throughout the continuum of healthcare represents the most valuable source 
in technology evaluation. However, in the European Union, the value assessment based on real-world data has become chal-
lenging as individuals have recently been given the right to have their personal data erased in the case of consent withdrawal 
or when the data are regarded as being no longer necessary. This act may limit the usefulness of data in the future as it may 
introduce information bias. Among healthcare stakeholders, this has become an important topic of discussion because it 
relates to the importance of data on one side and to the need for personal data protection on the other side, especially when 
it comes to “personal data related to the physical or mental health of a natural person, including the provision of health care 
services, which reveals information about his or her health status”. At the forefront of these discussions are data protection 
issues as well as the population’s trust in digital services. It seems that the new era has begun, where citizens and patients 
will have the ability to manage their personal or self-generated data. The European Commission has laid the groundwork 
for this paradigm shift that will steadily emerge in the coming years. To prepare for this change, we believe attention should 
be given to data security and other rules of data privacy. It has become increasingly important to ensure that individuals are 
properly introduced into complex environments with multiple sources of Big Data for clinical and behavioral purposes to 
provide an optimal balance between societal and individual benefits. In this article, a number of issues are considered and 
discussed, based upon the authors’ experience, with the aim of helping the reader better understand the implications of the 
use of Big Data and the importance of data protection in the coming years.
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1 Introduction
In Western European countries, the average life expectancy 
will increase by almost a year and the share of individuals 
aged 65 years and older in the total population will reach 
Key Points for Decision Makers 
Evaluation of new health technologies is becoming more 
difficult owing to a number of data protection issues 
related to how Big Data can be used to assess the per-
sonal preferences and behavior of individual customers.
The processes for limiting the use of data need to be 
systematic, transparent, and easy to handle.
Approaches to address data security and other principles 
of data privacy merit significant efforts to ensure that 
they are properly introduced.
Information exchange and interoperability have an 
important role in the secondary use of personal and clini-
cal data because the medical information of any indi-
vidual is and should be decentralized.
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how behavioral data can contribute to decision-making pro-
cesses in healthcare. For example, a cross-sectional regres-
sion model based upon 826 million tweets collected between 
June 2009 and March 2010 in the USA predicted atheroscle-
rotic heart disease mortality significantly better than a model 
that combined ten common demographic, socioeconomic, 
and health risk factors, including smoking, diabetes mellitus, 
hypertension, and obesity [13]. The analysis of behavioral 
data can ultimately help to change activities across the entire 
spectrum of disease development, including disease preven-
tion, early diagnosis, and treatment monitoring.
With the growing amount of available data, the concept 
of “data-driven innovation” has been launched. It refers to 
a significant improvement of existing products and services 
and development of new products or services. The emer-
gence of digital solutions and Big Data phenomena has also 
been acknowledged by the European Commission and its 
Horizon 2020 funding mechanism through the proposal of 
several activities linked to the Precommercial Procurement 
tool [14–17].
The European Union (EU) data economy represented 2% 
of the gross domestic product in 2016, and it was expected to 
reach 4% in 2020 [18]. In light of the growing importance of 
“data-driven innovation”, the EU initiated the development 
of the digital single market in 2015 [19]. The underlying 
rationale is to maximize the growth potential of the Euro-
pean digital economy and to ensure the right conditions for 
digital networks and services to grow and thrive. One of the 
key prerequisites for the development of the digital single 
market is the data protection and trust in digital services 
amongst the population [20].
The General Data Protection Regulation (GDPR) [21] 
came into force in May 2018 to harmonize and unify the 
legal regulation across the EU. The key focus of the GDPR 
is to foster innovation while strengthening the privacy rights 
of individuals [22, 23]. It offers a new set of rules designed 
to give EU citizens more control over their personal data 
[23] and it provides rules for the protection and processing 
of personal data [24].
To a great extent, the GDPR has already been analyzed 
by many experts [24–26]. Nevertheless, to our knowledge, 
there has been limited discussion regarding its impact on the 
growing role of Big Data in decision making in healthcare. 
It is therefore important to consider how the rules of data 
privacy are being implemented in such a complex environ-
ment with multiple sources of both clinical and behavioral 
data. An ever-increasing number of comprehensive datasets 
are available that allow researchers not only to gain insights 
into the efficacy of treatments, but also to analyze genetic 
information and utilize self-generated data from mobile 
applications, wearables, and social media [11, 27].
In this article, we focus on two frequently mentioned 
issues with the implementation of the GDPR in the 
22% by 2022 [1]. As a consequence of aging and medi-
cal innovation, global healthcare spending is expected to 
increase at an annual rate of 5.4% until 2022. It is nearly 
twice as much as the rates observed during the period 
2013–2017 [1]. In the search for the best approach towards 
the distribution of a limited healthcare budget, the “value 
for money” concept has been adopted most often [2, 3]. It 
refers to the amount of health outcomes achieved in a given 
budget. The value for money introduced a new dimension 
to evidence-based decision making that requires a greater 
reliance on different types of data in allocative choices in 
healthcare.
In 2017, The ‘Economist’ declared data, and not oil, as 
the world’s most valuable resource of the twenty-first cen-
tury [4]. The growing “digital universe” explains this shift. 
Data production is estimated to increase from fewer 50 cur-
rently to 175 zettabytes in 2025 [5]. Professor Klaus Schwab 
proclaimed that we are witnessing the birth of the fourth 
industrial revolution, which is fueled by a staggering moun-
tain of data. As he notes, it is “characterized by a range of 
new technologies that are fusing the physical, digital and 
biological worlds, impacting all disciplines, economies and 
industries, and even challenging ideas about what it means 
to be human” [6].
The amount of available data is growing in the health-
care sector as well. For example, in Sweden alone, there are 
103 health registries [7]. In an Organization for Economic 
Co-operation and Development study in 2016, 23 out of 28 
countries reported the implementation of electronic health 
records [8]. In the USA, while only 9% of non-federal acute 
care hospitals had a basic electronic health record in 2008, 
this percentage had risen to 96% in 2014 [9]. New health 
data sources are emerging as well. There are as many as 
325,000 mobile health apps available and more are being 
launched regularly [10]. With the growing velocity, variety, 
volume, and veracity of data, we are entering the era of Big 
Data.
Many examples are already available that illustrate how 
much Big Data are reshaping decision-making processes 
in healthcare. For instance, the analysis of genetic records 
of 35,000 patients enabled the discovery of a genetic vari-
ant related to schizophrenia [11]. Another example is the 
study of 7700 brain images from 1171 people that led to 
the discovery of the first physiological sign of Alzheimer’s 
disease resulting from decreased blood flow in the brain 
[12]. Beyond the clinical records of an individual’s medi-
cal history, diagnoses, laboratory results, prescriptions, and 
healthcare service consumption, there is a growing amount 
of behavioral data to contend with. It is mainly the digital 
footprint left after the adoption of different devices that col-
lect health-relevant information, such as dietary patterns, 
smoking habits, daily activities, and sleep–wake cycles. 
There is an ever-growing number of significant examples of 
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healthcare sector. First, we address the question of how to 
ensure GDPR-compliant research in the era of “patient-
centric” data ownership. Second, we discuss how to ensure 
free data transfer across multiple and diverse health data 
sources. Both issues are especially important for evidence 
generation as a basis for health technology evaluation in the 
new era of Big Data.
2  How to Ensure General Data Protection 
Regulation (GDPR) Compliant Research 
in the Era of ‘Patient‑Centric’ Data 
Ownership?
The GDPR defines health-related data as “personal data 
related to the physical or mental health of a natural person, 
including the provision of health care services, which reveal 
information about his or her health status” [28].
2.1  Why is Consent a Key Element of the GDPR?
The provision of consent to the processing of personal data 
is the most obvious legal requirement when the data are 
directly collected from subjects. However, for consent to 
have a valid legal basis, it must be: (1) freely given; (2) 
specific; (3) informed; and (4) unambiguous. The first crite-
rion means the consent must be a real choice of the subject 
and that the subject is in control of the provided informa-
tion [28]. The second criterion of specificity is linked to 
the purpose limitation: the data subject’s consent relates to 
the specific purpose of processing and cannot be used for 
alternative purposes. The third criterion for the consent to 
be informed means that adequate information must be pro-
vided to the data subject to enable him or her to make the 
informed choice. The information requirement is linked to 
the principle of transparency. The patient must at least have 
information on the identity of the “controller” (organizations 
that process personal data), the (type of) data collected and 
used, the existence of the right to withdraw consent, the 
potential use of the data for automated decision making (if 
relevant), as well as the possible risks involved with data 
transfers outside of the European Economic Area, if appli-
cable [26]. The fourth and final criterion is unambiguity (or 
clarity), which means that the consent must be provided in 
the form of a precise statement that requires clear affirmative 
action (an opt-in; not necessarily in the form of an opt-in 
box, but also as a signature or oral confirmation). Whenever 
possible, consent should be gathered in a written form, as it 
will make it easier to demonstrate the consent’s validity, if 
necessary [28].
It has to be emphasized that the consent to participate 
in a study or a trial must be distinguished from the consent 
to the processing of personal data [29–31]. Data protection 
legislation only governs the processing of personal data in 
the frame of research and has little bearing on the actual 
participation of individuals in research projects.
The GDPR recognizes that allowances must be made 
when the processing is carried out for scientific research pur-
poses. Therefore, the terms “broad concept” and “dynamic 
consent” were introduced.
The broad concept refers to the circumstances when “it is 
often not possible to fully identify the purpose of personal 
data processing for scientific research purposes at the time of 
data collection. Therefore, data subjects should be allowed to 
give their consent to certain areas of scientific research when 
in keeping with recognized ethical standards for scientific 
research” [28]. An Independent European Advisory Body on 
data protection and privacy (Article 29) further specifies that 
broad consent may be an option when the purpose cannot be 
fully explained at the onset of the project [32].
The alternative to “broad concept” is “dynamic consent”, 
which consists of using an IT solution, such as an app or a 
platform, to engage individuals and have active participants. 
This makes it possible to easily inform research participants 
and ask for re-consent or additional consent. “This approach 
is “dynamic” because it allows interactions over time; it ena-
bles participants to consent to new projects or to alter their 
consent choices in real time as their circumstances change 
and to have confidence that these changed choices will take 
effect” [33]. The advantages of dynamic consent appear to 
be numerous. In particular, it would be easier to seek re-
consent from data subjects. It would also facilitate the re-use 
and further processing of the data and ease the possibility 
of withdrawal. However, dynamic consent also has some 
drawbacks. It might limit the possibility for the engagement 
in research only to those having access to the appropriate 
electronic devices and applications and would inevitably 
lead to additional implementation costs.
2.2  Is Consent the Only Option for Researchers 
to Access the Data According to the GDPR?
Given the importance assigned to consent, one may con-
sider the feasibility of complying with such strict regulations 
when collecting data for research purposes. In the age of Big 
Data, however, research occupies a privileged position in 
the GDPR [24]. It adopts a “broad” definition of research. 
It encompasses the activities of public and private entities. 
Article 89 and related Recital 159 elaborate on “technologi-
cal development and demonstration, fundamental research, 
applied research and privately funded research.” When con-
sent might pose significant challenges, the GDPR introduces 
five other legal bases described in Article 6 (1) that can be 
chosen to justify the collection and processing of personal 
data [21].
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The most commonly used legal basis for research at pub-
lic universities is the notion of “public interest”. Research-
ers may meet that requirement by referring to the legal acts 
indicating that a given activity is fulfilling the purposes of 
the organization. Research should be dedicated to address-
ing societal challenges and providing long-term benefits to 
humanity. In the case of non-public research institutions, 
the “legitimate interests” may be a more appropriate law-
ful basis for processing personal data. This is a broad term 
that lacks a strict definition. Generally, it refers to the cir-
cumstances when the data processing takes place within an 
already established client-provider relationship. Hence, its 
usefulness for research may be limited [34].
2.3  May Public or Legitimate Interests be a Legal 
Basis Instead of Consent for Research According 
to the GDPR?
The GDPR has been the subject of intense debate, in par-
ticular concerning its potential effect on scientific research 
[35]. While the initial proposal of the Commission provided 
the option to carry out scientific research on a legal basis 
other than consent, the European Parliament Committee on 
Civil Liberties introduced a revision requiring that “con-
sent should always form the correct basis for the processing 
of personal health data in a research context unless such 
research serves a purpose of ‘exceptionally high public inter-
est’”. It also recommended that “where possible, health data 
was to be anonymized or at least pseudonymized to the high-
est possible technical standards.” The European Parliament 
Committee on Civil Liberties justified its revision by arguing 
that processing sensitive data for scientific research was not 
as urgent or as compelling as public health or social protec-
tion; as a result, there was no need to provide an exception 
to the consent requirement [36]. At the time, there were 
serious concerns about whether this would hinder health 
research significantly. However, the Council of Ministers 
of the EU, the third actor of the EU legislative procedure, 
did not agree with the obligatory consent and the request 
for a fully anonymized approach favored by the Parliament; 
as a consequence, the text finally adopted in 2016 provides 
for derogations. Nevertheless, the literature still refers to 
the consent as the first possible legal ground, fostering the 
impression that consent is the principle, and the rest is an 
exception.
There is still one key distinction between the secondary 
processing of previously collected data for research purposes 
and the projects where research is the primary purpose. The 
consent provided for the primary processing of personal data 
may be withdrawn at any time, and this introduces a factor 
of uncertainty in a research project. If data subjects exercise 
their right to withdraw, the processing of their data must 
stop.
In the case of secondary processing of previously col-
lected data, organizations may process personal data without 
consent, when “processing is necessary for the purposes of 
the legitimate interests pursued by the controller or by a 
third party, except where such interests are overridden by 
the interests or fundamental rights and freedoms of the data 
subject” [Article 6(1)(f)] [21]. Therefore, when a research 
project is carried out on a different legal basis such as legiti-
mate interest or the public interest, data subjects may not 
withdraw consent. However, they may oppose the data pro-
cessing by other means, such as exercising their right to 
object to the data processing, which may also be derogated 
(or partially suppressed) in certain circumstances.
Although the GDPR aims to encourage innovation by 
relaxing some regulations on further processing of personal 
data for research purposes, the “data minimization princi-
ple” of Article 5 requires personal data to be “limited to 
what is necessary” to complete the task successfully. In other 
words, it allows for the processing of personal data only to 
the extent needed to fulfill the research purpose.
On that note, it must be mentioned that GDPR introduces 
a high degree of scrutiny regarding the processing of sensi-
tive data. Article 9 introduces a special category of data that 
includes among others, genetic and biometric data related 
to physical, physiological, or behavioral characteristics of 
a natural person as well as non-health-related information 
concerning political opinions and religious or philosophical 
beliefs. Unless there is an explicit consent given, these data 
cannot be accessed, except in specifically defined circum-
stances: for example, threats to public health and preventive 
or occupational medicine [21]. It should be stressed that 
explicit consent further raises the standards of the “regu-
lar” consent. The consent must be clearly and explicitly 
expressed by the subject, thereby leaving no place for mis-
interpretation. Explicit consent can be expressed in a written 
or spoken format, but an electronic format is acceptable as 
well. A signed written statement is an appropriate means of 
demonstrating consent in the case of a scientific research 
project [37].
2.4  How to Ensure that the Conducted 
Retrospective Data Analysis is Compliant 
with the GDPR?
Article 6.4 of the GDPR [21] indicates that the purpose of 
further processing must be compatible with the purpose of 
the initial processing. In this case, it is not necessary to use 
a legal basis other than the basis used for the initial pro-
cessing. This means that the research project may re-use 
an existing data set without relying on a new specific legal 
basis. When possible, data subjects should be informed and 
the research sponsor must ensure that all their obligations as 
controllers are respected; in particular, in the case of medical 
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research, the research sponsor must ensure that one of the 
exceptions of Article 9.2 [21] is applicable. In the case of 
further processing of scientific research, the controller can 
continue to rely on the legal basis of the initial process-
ing provided the appropriate safeguards are implemented in 
compliance with Article 89.1 [21], which governs process-
ing for scientific research purposes and triggers the scientific 
research regimen of the GDPR.
2.5  How May Pseudonymization Support 
Compliance with the GDPR in Scientific 
Research?
If a legal basis other than explicit consent has been imple-
mented or re-use of personal data without consent is planned, 
Article 6 lists additional requirements for data processing 
[21]. These additional requirements include the existence of 
appropriate safeguards, which may include pseudonymiza-
tion or anonymization [38]. Pseudonymization is really a 
new term introduced by the GDPR that has become a key 
gateway for researchers to ensure compliance with GDPR 
regulations. Article 3 defines pseudonymization as “The 
processing of personal data in such a way that the data can 
no longer be attributed to a specific data subject without the 
use of additional information” [21]. The identifiable parts of 
personal data are translated into unique artificial identifiers 
(pseudonyms). The GDPR requires the additional informa-
tion needed to re-identify the person to be kept separately 
from the pseudonymized data. Different pseudonymization 
methods are available. The simplest form is through scram-
bling, which involves mixing, or masking (the obfuscation 
of letters), where an important unique part of the data is 
hidden with random characters or other data. Certain parts 
of the GDPR explicitly refer to the use of another type of 
pseudonymization, namely encryption, which involves using 
an algorithm to transform plain text information into a non-
readable form (ciphertext). The encryption is a two-way 
function (encryption to encode the information and decryp-
tion to return it to its original form); this differs from hash-
ing, which is a cryptographic one-way function without the 
possibility of decryption. Another type of pseudonymization 
is tokenization, which, unlike encryption, does not use a 
mathematical process and instead transforms the sensitive 
data into a token (a random string of characters). Tokeniza-
tion uses a database, called a token vault, which stores the 
relationship between the sensitive data and the token. The 
real data in the vault are secured, often via encryption [39].
The alternative to pseudonymization is anonymization, 
where the identifiable information is fully masked. Article 
4 and the related Recital 26 [21] define anonymized data as 
“data rendered anonymous in such a way that the data sub-
ject is not or no longer identifiable.” Anonymization places 
the processing and storage of data outside the scope of the 
GDPR because the data are no longer personal.
It is important to note that pseudonymization, anonymi-
zation, and de-identification techniques can only reduce the 
privacy risk for uncovering sensitive patient data. As such, 
de-identified data still need extensive data protection meas-
ures and patient consent procedures. Several techniques, 
like those described above, are proposed and the most com-
mon of them are found in the “IHE Information Technology 
Infrastructure Handbook on De-Identification” created by 
the non-profit organization named “Integrating the Health-
care Enterprise” [40].
2.6  How does the GDPR Align with National 
Regulations Regarding Research?
The regimen described above is applicable at the European 
level, but national legislation should still be carefully consid-
ered. Some provisions in the GDPR provide the possibility 
to the EU Member States to further legislate on some spe-
cific points, such as the possible derogations to data subject 
rights in the frame of scientific research or processing of 
data concerning health, genetic, and biometric data (Article 
89.2 of the GDPR) [21].
The Member States retain the possibility of introducing 
or maintaining further conditions, including limitations, 
concerning the processing of health data, genetic data, and 
biometric data (Article 9.4) [21]. In practice, this means that 
the conditions for use of data will not be the same from one 
Member State to the other. Obviously, this could negatively 
impact transnational European research projects. Still, the 
additional requirements should not limit the free flow of 
personal data within the EU with a special focus on cross-
border activities (Recital 53) [21]. The possible variation in 
the applicable rules in different Member States may compli-
cate the application of cross-border projects. As, however, 
the basis for the data processing will remain the same, such 
challenges should be resolvable.
3  How Can we Ensure Free Data Sharing 
Across Multiple and Diverse Health Data 
Sources?
3.1  How to Ensure that Data Sharing is Compliant 
with the GDPR?
The term “Big Data analytics” refers to the technical or ana-
lytical methods to extract information from multiple com-
plex data sets [41]. Big Data analytics commonly rely on 
existing data sets collected for other purposes, and this is 
therefore considered as further processing.
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Sharing personal data is a processing activity that is sub-
ject to the rules of the GDPR unless the data have been 
adequately anonymized. If Big Data analytics is used for 
scientific research, then the rules laid out earlier will apply; 
in particular, data subjects must be informed, if possible, and 
be given the possibility to exercise their rights. Recital 50 of 
the GDPR [21] clarifies that no legal basis separate from that 
which allowed the initial data collection is needed.
The fact that the further processing is for a different 
purpose does not necessarily mean that it is automatically 
incompatible; this needs to be assessed on a case-by-case 
basis, following the test of Article 6.4 of the GDPR [21]. 
If the new processing is not deemed incompatible with the 
initial processing, it may proceed, while still adhering to all 
the GDPR requirements.
If further processing is carried out by a different con-
troller than the initial controller, the data must be obtained 
from the initial controller. This requires access by the con-
troller to numerous data sets. Transfer of data is a process-
ing operation; therefore, transfer within the EU must be 
compliant with Chapter II of the GDPR [21]. Data may be 
shared between controllers based on a data-sharing agree-
ment organizing the responsibility of both controllers. Such 
an agreement could be a means for the initial controller to 
ensure the stewardship function. The data-sharing agreement 
may involve requirements as to the conditions and purposes 
of the processing, therefore, qualifying as a possible safe-
guard. It follows that data sharing must be envisaged from 
the beginning.
3.2  Will Patient Identifiers Support 
Interoperability?
The GDPR recognizes that data governance is an essential 
component of data sharing among institutions. That is why 
Recital 68 says, “Data controllers should be encouraged to 
develop interoperable formats that enable data portability” 
[21]. This necessity is formalized in the concept of data pro-
tection by design and by default.
The first concept of “privacy by design” focuses on 
integrating data protection into the product design process 
to ensure the inclusion of appropriate GDPR compliance 
measures. In contrast, the second requirement of “privacy 
by default” involves the restriction of processing of any per-
sonal data to the extent that is necessary for each specific 
business purpose.
The principles of data protection by design and by default 
bring together the legal and technical aspects of data protec-
tion. Privacy principles must be considered and implemented 
throughout the design cycle of processing. An example of 
where the principles must be carefully applied is the ability 
to easily identify the patient [42]. Efforts to implement a 
unique patient identifier across different databases can lead 
to errors in the patient healthcare continuum and increase the 
likelihood of privacy harm [43]. Health data are generated 
in multiple systems, and their integration may only be pos-
sible through a collaboration across different healthcare pro-
viders. This applies to all types of data used in healthcare, 
such as care plans, laboratory results, medical procedures, 
drug administration, community care, health records, and 
billing. With interoperable systems, data can be exchanged 
and stored automatically rather than re-typed into the system 
each time. Although presently data are still mainly collected 
through registries, healthcare systems are moving towards 
the holistic integrative analysis of multiple data sources, 
which will require specific expertise in data analytics. Data 
are not always available in a usable format, thus hinder-
ing the integration of data from various sources. As a solu-
tion to create a widely used and accepted data format, the 
integration profile process has been proposed as a way to 
enable end-to-end interoperability by sharing structured (and 
unstructured) data between the point-of-care systems [44].
3.3  New Challenges of Interoperability in the Era 
of the GDPR and Patient‑Centric Data Sharing
Interoperability in healthcare is often focused on data 
exchange between business entities. In the era of big data 
and digitalization, the shift happens towards patient-cen-
tered interoperability, meaning that a patient has full access 
to the data provided and is able to edit or delete it at any 
point. Among other factors, it is owing to the emergence of 
mobile health applications. Together with automated data 
collection from connected medical and wellness devices, 
the patient, and especially the empowered patient, can now 
contribute actively and create part of the Big Data needed 
for research and public health [45]. For example, ChatBots 
allow new direct communications today, between clinicians 
and patients [46, 47], empowering both of them in the form 
of shared care plans, direct communications, and chatting 
and artificial intelligence algorithms that drive data-driven 
innovation to a new era. From a practical point of view, 
security and privacy by design and interoperability by design 
are prerequisites to master GDPR and data privacy com-
pliance. Examples of system-embedded patient consent 
provision and revocation are now steadily emerging in the 
market, as well as proof of interoperability compliance and 
alignment to EU and other regulations [48]. All these new 
innovative tools are reshaping the medical software indus-
try from a procedural approach to digitize the clinical pro-
cess towards a workflow approach to digitize the interaction 
between patients and clinicians. As a result, software tools 
are now categorized as medical devices that fall under the 
regulation of the existing medical devices directive, soon 
to become the medical devices regulation [49, 50]. This is 
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a new compliance challenge that innovative solutions have 
to address from the design phase to data processing and re-
use phases.
3.4  How Can Blockchain Protect Data Sharing 
in the Era of the GDPR?
There is a growing interest in blockchain technology that 
could potentially address the two challenges of a patient’s 
identity and interoperability [51]. By definition, it allows a 
data owner to control his or her own medical records. Con-
sequently, it is up to that individual to share his or her data 
without any traditional intermediary. The blockchain allows 
the data owner to assign access rules (like smart contracts) 
for other data users. In other words, the blockchain creates 
an information-sharing marketplace. In principle, it offers a 
centralized and shared mechanism for the management of 
authentication and authorization rules surrounding data. In 
practice, a patient creates his or her own medical history by 
connecting to a particular healthcare provider interface (like 
a patient portal). Then, he or she grants that institution the 
access key, along with permission to securely transmit data 
(or metadata) to the blockchain. If it is done across multiple 
healthcare providers, medical data can be aggregated to cre-
ate a database.
One of the key components of the blockchain mechanism 
is the hashing function, which ensures both interoperability 
and security. Thanks to cryptographic algorithms, the patient 
data can be stored under unique identifiers while being safe 
and tamper proof. A ledger of hashes could be compared 
to the original data to prove it was not altered. Hence, the 
blockchain would allow for secure sharing of electronic 
medical information such as genomic data, clinical trial data, 
hospital, outpatient clinic, visiting nurse and immunization 
records, imaging and laboratory results, as well as pharmacy 
records, health data from mobile devices, wearables, and the 
“Internet of Things” at the click of a button. The potential 
issue of “blockchain technology” is the massive patenting 
spree, with over 114 pending patents granted (last updated 
5 March, 2019) [52]. For the interoperability to function, a 
blockchain needs to be a “universally accepted” open source, 
such as The Linux Foundation initiative Hyperledger Frame-
works (Fabric, Indy, Iroha) that makes software code open 
to the public. In addition, recent publications suggest that 
blockchain technology may apply to patient consent han-
dling without putting the medical information itself into the 
blockchain and instead only the consent/revocation informa-
tion from a procedural and legal perspective [53].
4  Conclusions
Big Data provide a multitude of opportunities to further 
develop the concept of value in the healthcare sector. Big 
Data facilitate the fight for better health by enabling faster 
identification of people at risk and better understanding of 
disease consequences [23]. Big Data analysis can help to 
combat rising health inequalities and improve the assess-
ment of the effectiveness of costly treatments [23]. As Arti-
cle 89 and the related Recital 157 in the GDPR explicitly 
state: “Registries provide solid, high-quality knowledge 
which can provide the basis for the formulation and imple-
mentation of knowledge-based policy, improve the quality 
of life for a number of people and improve the efficiency of 
social services”.
Personal data play a critical role in the development of 
data-driven healthcare. Still, it would be a great loss if we 
did not utilize the full potential of Big Data because of a 
lack of understanding of data privacy regulations. There-
fore, a sensitive balance needs to be struck between protect-
ing privacy and making the best use of health data. This is 
especially true with the growing availability of behavioral 
and digital data. Wearable and embedded devices (such as 
pacemakers, glucometers, and activity trackers) paired with 
remote monitoring and telemedicine services will ensure on-
time care and patient monitoring with minimal disruption of 
day-to-day activities.
With the stunning increase in the variety of different data 
sources available to demonstrate the ‘value for money’ in 
the healthcare sector, it is more crucial than ever to preserve 
any information that reveals a patient’s health status. Only 
when giving sufficient care to data security and other data 
protection principles, will we succeed to ensure that Big 
Data works to benefit all of the healthcare system stakehold-
ers and, more importantly, the patients. The future ahead 
clearly shows that people, devices, and the software will 
seamlessly interact to provide better care to the citizens. 
This, of course, empowers but also challenges health policy 
makers to develop appropriate safeguards for the data pri-
vacy in the EU and on a global scale. Difficult challenges 
will undoubtedly emerge and these will only be resolved 
properly if we clarify and agree on the trade-off between the 
health maximization and limits of the use of personal data.
On a positive note, there are already some encourag-
ing solutions within GDPR regulations that may actually 
encourage the growing use of data while keeping data pri-
vacy. For instance, the pseudonymization will inevitably 
help the Big Data industry to develop methods to grant 
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access to the personal health data for third parties. In due 
course, it will hopefully enable Big Data-driven health inno-
vation and advance interoperability frameworks while taking 
into account ethical and security risks in a new digital era. 
The GDPR provides the legal platform to incorporate data 
privacy by design and security by design as well. This will 
hopefully help the developers to adopt appropriate safety 
measures of data management during the clinical develop-
ment while limiting the risk of data privacy breaches. The 
GDPR should be seen as an enabler, not a barrier, to improve 
access to innovative digital health solutions in Europe. It has 
also increased the trend of renovation of laws and regula-
tions beyond the EU, which will hopefully allow safer re-use 
of patient-driven data for research and public health globally.
In conclusion, GDPR has introduced a new era of law-
ful data processing, where the real owner of the data is the 
individual citizen. As we have already started our journey 
towards patient-centric healthcare systems, it is interesting 
to the observer what is the next destination in front of us. 
One can wonder whether the current clinical or healthcare 
provider-driven point-of-care system will be replaced with 
personalized reimbursement models based on health out-
comes being reported on the individual level. Surely, the 
era of Big data welcomes us to the bright future. The data 
protection regulation is a traffic light system that ensures a 
very safe journey.
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